Tvardi Therapeutics
TVRD
128 hedge funds and large institutions have $211M invested in Tvardi Therapeutics in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 39 reducing their positions, and 20 closing their positions.
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
6% more funds holding
Funds holding: 121 → 128 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.71% less ownership
Funds ownership: 58.68% → 52.97% (-5.7%)
19% less capital invested
Capital invested by funds: $262M → $211M (-$50.1M)
28% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 39
30% less call options, than puts
Call options by funds: $4.36M | Put options by funds: $6.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.69M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.42M |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$1.61M |
| 4 |
First Manhattan
New York
|
+$1.29M |
| 5 |
Millennium Management
New York
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$20.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.61M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$3.19M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$2.2M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$1.95M |
TVRD Hedge Fund Activity: Q4 2017 in Review
128 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2017, worth a combined $211M — down 19% from $262M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TVRD positions and 20 closed out — a net gain of 7 holders — while 28 added to existing stakes and 39 trimmed.
The largest buyer was BlackRock, adding an estimated $5.69M. The largest seller was State Street, cutting an estimated $20.7M.
- 128 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2017, up from 121 in Q3 2017.
- Funds reported $211M of Tvardi Therapeutics stock for Q4 2017, down 19% quarter-over-quarter.
- 27 funds opened new Tvardi Therapeutics positions in Q4 2017 and 20 closed out, a net change of +7 holders.
- The largest Tvardi Therapeutics buyer in Q4 2017 was BlackRock, an estimated $5.69M added.
- The largest Tvardi Therapeutics seller in Q4 2017 was State Street, an estimated $20.7M sold.
Based on aggregated 13F filings for Q4 2017.